Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

K. Laribi · SciRah

Researcher profile · Semantic Scholar

K. Laribi

Share profile

K. Laribi — researcher profile on SciRah

h-index: 36
Works: 268
Citations: 5,564

Most-cited papers

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
X. Leleu, C. Hulin, J. Lambert, A. Bobin +57 more
2024Nature Medicine123 citations Open access
Semantic Scholar
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome
L. Veloza, D. Cavaliéri, E. Missiaglia, A. Ledoux-Pilon +31 more
2022Haematologica69 citations Open access
Semantic Scholar
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA
M. Shadman, T. Munir, T. Robak, Jennifer R. Brown +29 more
2024Journal of Clinical Oncology53 citations Open access
Semantic Scholar
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
N. Bartlett, Uwe Hahn, Won-Seog Kim, Isabelle Fleury +16 more
2025Journal of Clinical Oncology48 citations
Semantic Scholar
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs
M. Sobas, J. Kiladjian, Yan Beauverd, N. Curto-Garcia +41 more
2022Blood Advances41 citations Open access
Semantic Scholar
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
T. Chatzikonstantinou, L. Scarfò, Georgios Karakatsoulis, E. Minga +138 more
2023EClinicalMedicine22 citations Open access
Semantic Scholar
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment
S. Garciaz, P. Dumas, S. Bertoli, D. Sallman +24 more
2024American journal of hematology/oncology21 citations Open access
Semantic Scholar
Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)
K. Laribi, S. Poulain, L. Willems, F. Merabet +10 more
2024British Journal of Haematology20 citations
Semantic Scholar
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
A. Talbot, A. Bobin, Léa Tabone, J. Lambert +45 more
2023Haematologica19 citations Open access
Semantic Scholar
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial.
S. Manier, J. Lambert, C. Hulin, M. Macro +36 more
2025The Lancet Oncology18 citations Open access
Semantic Scholar
P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY
T. Munir, M. Shadman, T. Robak, Jennifer R. Brown +31 more
2023HemaSphere18 citations Open access
Semantic Scholar
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
J. Woyach, L. Qiu, S. Grosicki, T. Wrobel +24 more
2025Journal of Clinical Oncology17 citations Open access
Semantic Scholar
Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera
Yan Beauverd, J. Ianotto, K. Thaw, M. Sobas +42 more
2025Leukemia16 citations Open access
Semantic Scholar
The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma
S. Manier, J. Lambert, C. Hulin, K. Laribi +24 more
2024Blood16 citations
Semantic Scholar
Impact of Cytoreductive Drugs upon Outcomes in a Contemporary Cohort of Adolescent and Young Adults with Essential Thrombocythemia and Polycythemia Vera
Yan Beauverd, J. Ianotto, K. Thaw, M. Sobas +42 more
2023Blood16 citations Open access
Semantic Scholar
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial
Romain Guièze, Loïc Ysebaert, Damien Roos-Weil, L. Fornecker +24 more
2024Nature Communications13 citations Open access
Semantic Scholar
Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study
S. Garciaz, S. Bertoli, D. Sallman, J. Decroocq +14 more
2023Blood13 citations Open access
Semantic Scholar
S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
J. Mascarenhas, Tania Jain, Salman Otoukesh, A. Gerds +18 more
2023HemaSphere12 citations Open access
Semantic Scholar
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
A. Michallet, R. Letestu, M. Le Garff-Tavernier, L. Campos +29 more
2023Blood Advances11 citations Open access
Semantic Scholar
ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY
M. Shadman, T. Munir, T. Roback, J. Brown +31 more
2023Hematological Oncology11 citations Open access
Semantic Scholar
Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma
D. Vallois, E. Missiaglia, L. Veloza, A. Fischer +30 more
2025Leukemia8 citations Open access
Semantic Scholar
Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups
M. Sébert, Sylvie Chevret, S. Dimicoli-Salazar, T. Cluzeau +22 more
2024Blood8 citations Open access
Semantic Scholar
Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease
M. Lafargue, M. Bobot, H. Rennke, Marie Essig +17 more
2023Kidney International Reports8 citations Open access
Semantic Scholar
Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study
O. Tournilhac, K. Bouabdallah, Solene Lecolant, M. Hacini +39 more
2025Blood Advances7 citations Open access
Semantic Scholar
Fatigue visual analogue scale score correlates with quality of life in cancer patients receiving epoetin alfa (Sandoz) for chemotherapy-induced anaemia: The CIROCO study.
Jérôme Desramé, N. Baize, Amélie Anota, K. Laribi +5 more
2023Cancer Treatment and Research Communications7 citations Open access
Semantic Scholar
Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).
X. Leleu, C. Hulin, J. Lambert, A. Bobin +16 more
2024Journal of Clinical Oncology6 citations
Semantic Scholar
Phase 2 LYSA study of prednisone, vinblastine, doxorubicin, bendamustine for untreated older Hodgkin lymphoma patients.
H. Ghesquières, D. Krzisch, Emmanuelle Nicolas Virelizier, S. Kanoun +17 more
2023Blood6 citations Open access
Semantic Scholar
Achievement of rapid complete remission in an 87-year-old female patient with azacytidine-venetoclax for blastic plasmacytoid dendritic cell neoplasm
R. Le Calloch, B. Arnaud, L. Le Clech, P. Hutin +4 more
2022Annals of Hematology6 citations
Semantic Scholar
Response to vaccination against SARS‐CoV‐2 in 168 patients with Waldenström macroglobulinaemia: A French Innovative Leukaemia Organization study
C. Tomowiak, V. Leblond, K. Laribi, M. Baron +9 more
2022British Journal of Haematology6 citations
Semantic Scholar
CALR‐mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM
Laure Aubin, R. V. Vilas Boas, Rafael Daltro de Oliveira, Valoris Le Brun +31 more
2024American journal of hematology/oncology5 citations Open access
Semantic Scholar
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group
A. Michallet, R. Letestu, M. Legarff, S. Morisset +30 more
2024Blood5 citations
Semantic Scholar
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia
N. Short, Agnieszka Wierzbowska, T. Cluzeau, K. Laribi +14 more
2024Leukemia and Lymphoma5 citations Open access
Semantic Scholar
Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS)
A. Quinquenel, S. Leprêtre, M. Dilhuydy, L. Bussot +11 more
2025Annals of Hematology4 citations Open access
Semantic Scholar
Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM study
C. Orvain, S. Tavitian, Clémence Médiavilla, Françoise Boyer +29 more
2025HemaSphere4 citations Open access
Semantic Scholar
Waldenström's macroglobulinemia: The LYSA pragmatic guidelines.
Damien Roos-Weil, C. Tomowiak, Stéphanie Poulain, F. Nguyen-Khac +15 more
2025European Journal of Cancer4 citations Open access
Semantic Scholar
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy
Andrew H. Wei, P. Panayiotidis, P. Montesinos, K. Laribi +25 more
2025Blood Advances4 citations Open access
Semantic Scholar
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group
A. Quinquenel, R. Letestu, M. Le Garff-Tavernier, Stéphane Morisset +38 more
2025EClinicalMedicine4 citations Open access
Semantic Scholar
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.
Jeong A. Kim, Uwe Hahn, W. Kim, Isabelle Fleury +14 more
2024Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
T. Chatzikonstantinou, L. Scarfò, E. Minga, Georgios Karakatsoulis +119 more
2024HemaSphere4 citations Open access
Semantic Scholar
Real‐life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study
K. Laribi, X. Leleu, N. Texier, R. Germain +15 more
2023eJHaem4 citations Open access
Semantic Scholar
High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
J. Corre, J. Lambert, A. Bobin, S. Manier +49 more
2024Blood3 citations
Semantic Scholar
Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial
Sophie Park, B. Slama, Marius Moldovan, D. Rombaut +23 more
2024Blood3 citations
Semantic Scholar
Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)
S. Garciaz, J. Decroocq, S. Bertoli, A. Belhabri +11 more
2022Blood3 citations Open access
Semantic Scholar
Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies
Constantine S. Tam, M. Anderson, M. Šimkovič, P. Ghia +17 more
2025Blood Advances2 citations Open access
Semantic Scholar
Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma
N. Bartlett, Uwe Hahn, Won-Seog Kim, Isabelle Fleury +16 more
2025Future Oncology2 citations Open access
Semantic Scholar
Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
J. Woyach, L. Qiu, S. Grosicki, Tomasz Wróbel +22 more
2025Blood2 citations
Semantic Scholar
Targeted therapies overcome the poor prognosis of stereotyped Subset#2 chronic lymphocytic leukemia : a real-world multicentric study
L. Bussot, Stéphanie Poulain, Morgane Nudel Ortmans, F. Davi +49 more
2025Leukemia2 citations Open access
Semantic Scholar
Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination - a FIM Study
C. Orvain, S. Tavitian, Clémence Médiavilla, Françoise Boyer +27 more
2024Blood2 citations
Semantic Scholar
P650: EFFECTIVENESS OF VENETOCLAX ACCORDING TO THE CHARACTERISTICS OF PATIENTS WITH CLL IN MONOTHERAPY AND COMBINATION WITH RITUXIMAB. INTERIM ANALYSIS OF REAL-LIFE DATA FROM VERONE STUDY
L. Ysebaert, X. Troussard, Vincent Lévy, R. Le Calloch +9 more
2023HemaSphere2 citations Open access
Semantic Scholar
Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.
J. Lazarovici, Sandy Amorim, K. Bouabdallah, M. Fournier +22 more
2026Haematologica1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Leprêtre×9
Invite
S. Leprêtre — researcher profile on SciRah
R. Le Calloch×7
Invite
R. Le Calloch — researcher profile on SciRah
C. Touzeau×7
Invite
C. Touzeau — researcher profile on SciRah
S. de Guibert×7
Invite
S. de Guibert — researcher profile on SciRah

×7

Invite

J. Ianotto — researcher profile on SciRah

Invite

X. Leleu — researcher profile on SciRah

Invite

C. Hulin — researcher profile on SciRah

Invite

A. Perrot — researcher profile on SciRah

Lionel Karlin×6

Invite

Lionel Karlin — researcher profile on SciRah

A. Santagostino×6

Invite

A. Santagostino — researcher profile on SciRah

Invite

S. Manier — researcher profile on SciRah

O. Tournilhac×6

Invite

O. Tournilhac — researcher profile on SciRah